Evidence map›Paper›PMID 41184667›Full record

ArticlePituitary2025

Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas?

Nidhi Agrawal, Sonal Mehta, Richard A Feelders, Samara Skwiersky, Claudia Campana, Fadime Dogan, Peter M van Koetsveld, Sebastian J C M M Neggers, Kyla Wright, Hyon Kim and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nidhi AgrawalNew York University Langone Medical Center, New York, NY, USA.
Sonal MehtaNew York University Langone Medical Center, New York, NY, USA.
Richard A FeeldersDepartment of Internal Medicine, Division of Endocrinology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
Samara SkwierskyNYU Langone Health - Long Island, Mineola, NY, USA.
Claudia CampanaDepartment of Internal Medicine, Division of Endocrinology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
Fadime DoganDepartment of Internal Medicine, Division of Endocrinology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
Peter M van KoetsveldDepartment of Internal Medicine, Division of Endocrinology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
Sebastian J C M M NeggersDepartment of Internal Medicine, Division of Endocrinology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands.
Kyla WrightDepartment of Surgery, University of California Los Angeles Health, Los Angeles, CA, USA.
Hyon KimRobert Wood Johnson Barnabas Health, West Orange, NJ, USA.
David ZagzagNew York University Langone Medical Center, New York, NY, USA.
Leo J HoflandDepartment of Internal Medicine, Division of Endocrinology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands. l.hofland@erasmusmc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of prolactinomas are treated with dopamine agonists (DA) with excellent response, however DA-resistance occurs in 10% of prolactinomas. Somatostatin (SST) receptors have been increasingly studied in prolactinomas. There are five SST receptor subtypes and a significant number of prolactinomas show expression of SST

Indexed as

Pituitary NeoplasmsProlactinomaReceptors, SomatostatinSomatostatinAdultAgedCabergolineDopamine AgonistsFemaleHumansMaleMiddle AgedOctreotideProlactinReceptors, Dopamine D2Retrospective StudiesCabergolineDopamine AgonistsOctreotidepasireotideProlactinReceptors, Dopamine D2Receptors, SomatostatinSomatostatinsomatostatin receptor 5CabergolineDopamineOctreotidePasireotideProlactinomaReceptorResistanceSomatostatin

Identifiers

PMID41184667
PMCPMC12583388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.